Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(7):935–938. doi: 10.1038/bjc.1997.487

Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance.

C Pepper 1, T Hoy 1, D P Bentley 1
PMCID: PMC2228064  PMID: 9328155

Abstract

The bcl-2 gene is overexpressed in the absence of gene rearrangements in most cases of B-cell chronic lymphocytic leukaemia (B-CLL) and the proto-oncogene product Bcl-2 has been shown to be a regulator of apoptosis. The activity of this protein is opposed by Bax, a homologous protein that accelerates the rate of cell death. B-lymphocyte Bcl-2 and Bax protein levels were found to be significantly altered in B-CLL and increased Bcl-2/Bax ratios were observed in both the treated and untreated patients compared with those of normal controls. These alterations were particularly pronounced in those treated patients found to be clinically unresponsive to chemotherapy. In order to determine whether Bcl-2/Bax ratios affected cell survival via an anti-apoptotic mechanism, cell death was induced in B-CLL cells in vitro using chlorambucil, and apoptosis was monitored by Annexin V and propidium iodide staining. Confirmation that the labelled cells were apoptotic was achieved by morphological assessment of cytospin preparations of cell-sorted populations. Drug-induced apoptosis in B-CLL cells was inversely related to Bcl-2/Bax ratios.

Full text

PDF
935

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Begleiter A., Lee K., Israels L. G., Mowat M. R., Johnston J. B. Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia. 1994 Apr;8 (Suppl 1):S103–S106. [PubMed] [Google Scholar]
  2. Binet J. L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1;48(1):198–206. doi: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  3. Cheson B. D., Bennett J. M., Rai K. R., Grever M. R., Kay N. E., Schiffer C. A., Oken M. M., Keating M. J., Boldt D. H., Kempin S. J. Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group. Am J Hematol. 1988 Nov;29(3):152–163. doi: 10.1002/ajh.2830290307. [DOI] [PubMed] [Google Scholar]
  4. Collins R. J., Verschuer L. A., Harmon B. V., Prentice R. L., Pope J. H., Kerr J. F. Spontaneous programmed death (apoptosis) of B-chronic lymphocytic leukaemia cells following their culture in vitro. Br J Haematol. 1989 Mar;71(3):343–350. doi: 10.1111/j.1365-2141.1989.tb04290.x. [DOI] [PubMed] [Google Scholar]
  5. Gottardi D., Alfarano A., De Leo A. M., Stacchini A., Bergui L., Caligaris-Cappio F. Defective apoptosis due to Bcl-2 overexpression may explain why B-CLL cells accumulate in G0. Curr Top Microbiol Immunol. 1995;194:307–312. doi: 10.1007/978-3-642-79275-5_35. [DOI] [PubMed] [Google Scholar]
  6. Hanada M., Delia D., Aiello A., Stadtmauer E., Reed J. C. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood. 1993 Sep 15;82(6):1820–1828. [PubMed] [Google Scholar]
  7. Oltvai Z. N., Milliman C. L., Korsmeyer S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993 Aug 27;74(4):609–619. doi: 10.1016/0092-8674(93)90509-o. [DOI] [PubMed] [Google Scholar]
  8. Pepper C., Bentley P., Hoy T. Regulation of clinical chemoresistance by bcl-2 and bax oncoproteins in B-cell chronic lymphocytic leukaemia. Br J Haematol. 1996 Dec;95(3):513–517. doi: 10.1046/j.1365-2141.1996.d01-1927.x. [DOI] [PubMed] [Google Scholar]
  9. Reed J. C. Bcl-2 family proteins: regulators of chemoresistance in cancer. Toxicol Lett. 1995 Dec;82-83:155–158. doi: 10.1016/0378-4274(95)03551-6. [DOI] [PubMed] [Google Scholar]
  10. Robertson L. E., Plunkett W. Apoptotic cell death in chronic lymphocytic leukemia. Leuk Lymphoma. 1993;11 (Suppl 2):71–74. doi: 10.3109/10428199309064265. [DOI] [PubMed] [Google Scholar]
  11. Robertson L. E., Plunkett W., McConnell K., Keating M. J., McDonnell T. J. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996 Mar;10(3):456–459. [PubMed] [Google Scholar]
  12. Thomas A., El Rouby S., Reed J. C., Krajewski S., Silber R., Potmesil M., Newcomb E. W. Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: relationship between p53 gene mutation and bcl-2/bax proteins in drug resistance. Oncogene. 1996 Mar 7;12(5):1055–1062. [PubMed] [Google Scholar]
  13. Vermes I., Haanen C., Steffens-Nakken H., Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods. 1995 Jul 17;184(1):39–51. doi: 10.1016/0022-1759(95)00072-i. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES